Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects-Reference-Cited by-同舟云学术

Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects

Published:2023 Issue:2 Volume:31 Page:105
ISSN:2289-0882
Container-title:Translational and Clinical Pharmacology
language:en
Short-container-title:Transl Clin Pharmacol

Author:

Lee Hae Won¹^ORCID,Kang Woo Youl²^ORCID,Park Ji Seo¹,Lee Jae Hwa¹,Gwon Mi-Ri¹^ORCID,Yang Dong Heon³,Kim Eun Hee⁴,Park Soo-Jin⁵,Yoon Young-Ran¹^ORCID,Seong Sook Jin¹^ORCID

Affiliation:

1. School of Medicine, Kyungpook National University and Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea.

2. Clinical Trial Dossier Evaluation Team, Department of Innovative Products Support, National Institute of Food and Drug Safety Evaluation, Cheongju 28159, Korea.

3. Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu 41944, Korea.

4. College of Nursing, Catholic University of Daegu, Gyeongsan 38430, Korea.

5. College of Korean Medicine, Daegu Haany University, Daegu 38610, Korea.

Funder

KyungDong Pharmaceutical Corp. Ltd.

Korea Health Industry Development Institute

Publisher

XMLink

Subject

Pharmacology (medical)

Link

https://tcpharm.org/pdf/10.12793/tcp.2023.31.e10